- A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment. [Journal Article]
- As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naïve high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherapy for up to 8 weeks, followed up until 24 months. At week 8, 50.0% of the patients were able to ach…
- PMC Free PDF
- A novel integrated biomarker index for the assessment of hematological responses in MPNs during treatment with hydroxyurea and interferon-alpha2. [Journal Article]Cancer Med. 2022 Oct 17 [Online ahead of print]CM
- CONCLUSIONS: This novel tool convincingly displays the superiority of IFN versus HU in normalizing elevated cell counts. Our results need to be validated in larger studies but already now call for studies of the safety and efficacy of combination therapy during the initial treatment of patients with MPNs.
- Publisher Full Text (DOI)
- A Young Adult With Essential Thrombocythemia Presenting as Myocardial Infarction. [Case Reports]
- Essential thrombocythemia (ET) is a myeloproliferative neoplasm involving the clonal proliferation of platelets. It is Philadelphia negative and is associated with Janus kinase 2 (JAK2), calreticulin (CALR), or myeloproliferative leukemia virus oncogene (MPL) mutations. The resultant platelets have quantitative and qualitative defects, making them more sticky and prone to thromboembolism. However…
- PMC Free PDF
- Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population. [Journal Article]Leuk Res. 2022 12; 123:106962.LR
- According to the current treatment recommendations, anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy for patients with high-risk essential thrombocythemia experiencing intolerance or refractoriness to first-line approach, such as hydroxyurea or pegylated interferon alpha-2a. If there is a need for introduction of cytoreductive treatment in young patients with a pers…
- Publisher Full Text (DOI)
- MPN-545 Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia. [Randomized Controlled Trial]
- CONCLUSIONS: Results will provide the first evidence of a second-line ET treatment by comparing P1101 with the only approved treatment option, ANA. This study is sponsored by PharmaEssentia USA.
- Publisher Full Text (DOI)
- MPN-546 A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia. [Multicenter Study]Clin Lymphoma Myeloma Leuk. 2022 10; 22 Suppl 2:S342-S343.CL
- There is an unmet need for treatment options for patients with essential thrombocythemia (ET) who require cytoreduction who may or may not have been treated with hydroxyurea (HU) or anagrelide (ANA), which is commonly used outside of North America. In addition to the reduction of thrombotic risk, treatment options for ET should reduce all blood cell types, prevent disease progression, and modify …
- Publisher Full Text (DOI)
- MPN-186 Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden: Analysis of Data from the MOST Study. [Journal Article]Clin Lymphoma Myeloma Leuk. 2022 10; 22 Suppl 2:S329.CL
- CONCLUSIONS: Real-world data demonstrate similar care between AC and CC. The clinical significance of key differences in demographics, disease features, and treatment history remains unclear. Understanding these will help improve disease management across sites. Older and minority populations in CC may represent a key population for clinical trial recruitment.
- Publisher Full Text (DOI)
- Surgical Complications in Myeloproliferative Neoplasm Patient with Essential Thrombocythemia: A Case Report. [Case Reports]
- CONCLUSIONS: Myeloproliferative disease patients with high thrombocyte count are subjected to increased risk of thrombotic complications in perioperative settings, thus perioperative management and risk assessment are important to improve quality of life and prevent complications. Surgery in MPN patients with elevated thrombocytes may be considered if the benefits outweigh the risks. More studies in this field should be conducted in-order to provide more data for a guideline or systematic review/meta-analyses.
- PMC Free PDF
- CDH6 as a prognostic indicator and marker for chemotherapy in gliomas. [Journal Article]
- Glioma is the most malignant cancer of the central nervous system. There are various therapies for treating gliomas, but their outcomes are not satisfactory. Therefore, new targets for glioma treatment are needed. This study examined the cadherin-6 (CDH6) expression in gliomas using The Cancer Genome Atlas and Chinese Glioma Genome Atlas datasets. CDH6 expression positively correlated with the Wo…
- PMC Free PDF
- SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. [Review]Future Oncol. 2022 Sep; 18(27):2999-3009.FO
- Patients diagnosed with high-risk essential thrombocythemia (ET) have limited treatment options to reduce the risk of thrombosis and lessen the progression of the disease by targeting the molecular source. Hydroxyurea is the recommended treatment, but many patients experience resistance or intolerance. Anagrelide is an approved second-line option for ET, but concerns of a higher frequency of dise…
- Publisher Full Text (DOI)
- Anagrelide-Induced Supraventricular Tachycardia: A Case Report. [Case Reports]
- Anagrelide is an inhibitor of the phosphodiesterase-3 (PDE-3) enzyme that suppresses megakaryocytes; hence it is used in the treatment of essential thrombocythemia. Anagrelide can cause positive inotropic and chronotropic effects on the cardiovascular system. Its cardiovascular side effects are rare and include palpitations, tachyarrhythmias, cardiomyopathy, angina, and heart failure. We report t…
- PMC Free PDF
- Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database. [Journal Article]Leuk Res. 2022 08; 119:106903.LR
- Anagrelide (ANA) is a platelet-specific cytoreductive agent utilized in the guideline-directed management of high-risk essential thrombocythemia. In the context of polycythemia vera (PV), ANA is occasionally employed in clinical practice, although data has not consistently demonstrated a benefit to targeting a platelet goal as a therapeutic endpoint. The aim of the current study was to delineate …
- Publisher Full Text (DOI)
- Resurgence of myeloproliferative neoplasm in patients in remission from blast transformation after treatment with hypomethylating agents. [Journal Article]Leuk Res. 2022 07; 118:106871.LR
- Subsequent blast (BP) or accelerated phase (AP) is a severe complication of Philadelphia-negative myeloproliferative neoplasms (MPNs). The prognosis is generally dismal, but hypomethylating agents (HMAs) may induce a long-lasting response in a minority of patients. Here, we report a cohort of six patients with BP/AP-MPN who experienced MPN relapse after a leukemia response was obtained with azacy…
- Publisher Full Text (DOI)
- Safety and efficacy of anagrelide in Japanese post-marketing surveillance, with subgroup analyses on the effect of previous cytoreductive therapies, age, and starting dose. [Journal Article]
- CONCLUSIONS: This surveillance showed that anagrelide has a tolerable safety and efficacy profile.
- PMC Free PDF
- Essential thrombocythemia with CALR mutation and recurrent stroke: two case reports and literature review. [Case Reports]
- Cerebrovascular events, especially ischemic stroke, are common complications of essential thrombocythemia (ET). Compared to JAK2V617 F mutation, CALR mutation is considered as a lower risk factor of thrombosis in ET. Until now stroke in ET with CALR mutation has rarely been reported. We retrospectively investigated patients diagnosed with stroke and ET in Xijing hospital of Air Force Medical Univ…
- PMC Free PDF
- Anagrelide-associated Cardiomyopathy and Heart Failure in a Patient with Essential Thrombocythemia: A Case Report and Literature Review. [Case Reports]
- Anagrelide is used worldwide to treat essential thrombocythemia (ET) by reducing platelet counts. Cardiomyopathy and heart failure (HF) are rare but serious complications associated with anagrelide use, although no cases were reported during Japanese Phase I to III studies. A 46-year-old, otherwise healthy, Japanese ET patient developed HF with reduced ejection fraction after 18 months of treatme…
- PMC Free PDF
- Antagonistic L1 Adhesion Molecule Mimetic Compounds Inhibit Glioblastoma Cell Migration In Vitro. [Journal Article]
- Cell adhesion molecule L1 is a cell surface glycoprotein that promotes neuronal cell migration, fosters regeneration after spinal cord injury and ameliorates the consequences of neuronal degeneration in mouse and zebrafish models. Counter-indicative features of L1 were found in tumor progression: the more L1 is expressed, the more tumor cells migrate and increase their metastatic potential. L1's …
- PMC Free PDF
- Interaction of Anagrelide drug molecule on pristine and doped boron nitride nanocages: a DFT, RDG, PCM and QTAIM investigation. [Journal Article]
- Nowadays, a nanostructure-based drug delivery system is one of the most noticeable topics to be studied, and in this regard, boron nitride nanoclusters are promising drug carriers for targeted drug delivery systems. In this article, the interaction mechanism of Anagrelide (AG) drug with B12N12 and Al- and Ga-doped B12N12 nanocages have been investigated using DFT with B3LYP/6-31 G (d, p) method i…
- Publisher Full Text (DOI)
- Platelet Anti-Aggregator Drowns the Heart. [Case Reports]S D Med. 2021 Nov; 74(11):502-505.SD
- CONCLUSIONS: Anagrelide is considered to be very effective treatment for essential thrombocytosis. It is, however, associated with serious adverse effects such as pericardial effusion, liver toxicity and palpitations. The mechanisms of these adverse drug reactions are still not completely understood. We suggest that patient taking anagrelide presenting with shortness of breath should have a transthoracic echocardiogram performed to rule out pericardial effusion. Liver enzymes should also be monitored closely and anagrelide discontinued immediately if the above-mentioned adverse events are noted.
- A toe ulcer in a patient with essential thrombocythemia successfully treated with a combination of anagrelide and prednisolone. [Letter]Dermatol Ther. 2022 02; 35(2):e15221.DT
- Publisher Full Text (DOI)
- Structure of PDE3A-SLFN12 complex and structure-based design for a potent apoptosis inducer of tumor cells. [Journal Article]
- Molecular glues are a class of small molecular drugs that mediate protein-protein interactions, that induce either the degradation or stabilization of target protein. A structurally diverse group of chemicals, including 17-β-estradiol (E2), anagrelide, nauclefine, and DNMDP, induces apoptosis by forming complexes with phosphodiesterase 3A (PDE3A) and Schlafen 12 protein (SLFN12). They do so by bi…
- PMC Free PDF
- The Clinical Significance of Circulating Microparticles Concerning Thrombosis in BCR/ABL1-negative Myeloproliferative Neoplasms. [Journal Article]
- CONCLUSIONS: The relationship with thrombotic risk factors indicates a possible role of MPs in the complex thrombotic mechanism, though cytoreductive treatment seems to affect this role through reducing MP levels.
- PMC Free PDF
- Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. [Practice Guideline]
- Recommendations regarding management of essential thrombocythaemia rely on studies done before the discovery of the CALR mutation. On May 20, 2020, the European LeukemiaNet annual meeting was held with the goal to identify unmet clinical needs in myeloproliferative neoplasms. Because patients with a CALR mutation have specific clinical characteristics, treatment of CALR-mutated essential thromboc…
- Publisher Full Text (DOI)
- Bone marrow morphological features and therapy in patients with Philadelphia-negative neoplasms. [Review]
- Introduction Chronic myeloproliferative neoplasm (MPNs) are clonal malignant bone marrow (BM) diseases, arising from a hematopoietic stem cell. All therapies for these neoplasms have peculiar effects on the bone marrow, but little evidence has been described in the literature.Areas covered This review examines BM morphological changes following the main treatments in Philadelphia-negative MPNs. H…
- Publisher Full Text (DOI)
- Essential Thrombocythemia in Children: A Retrospective Study. [Journal Article]
- CONCLUSIONS: The incidence of ET in children is extremely low in Saudi Arabia. Most of the children with ET were asymptomatic, and thrombocytosis was often discovered incidentally. JAK2 V617F mutation has no known impact on the prognosis or on the outcome of the disease in the pediatric age group that is in contrast to the adult ET. Children less than 1 year are at high risk for complications particularly during acute precipitating infectious episode. The potential complications and clinical course of pediatric ET are unpredictable.
- PMC Free PDF
- Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms. [Letter]Pharmacology. 2021; 106(7-8):451-452.P
- Publisher Full Text (DOI)
- Advances in the Treatment of Polycythemia Vera: Trends in Disease Management. [Review]
- Treatment modalities for polycythemia vera (PV) have evolved over time. Phlebotomy and low-dose aspirin suffice in low-risk patients, but cytoreductive therapies are indicated in all high-risk patients (age ≥ 65 years or those with a history of PV-related thrombotic event) and may be considered for low-risk patients with progressively increasing splenomegaly, progressively increasing leucocyte an…
- PMC Free PDF
- Leg ulcer with long-term hydroxyurea use. [Journal Article]
- Long-term use of hydroxyurea can cause leg ulcers which usually do not heal unless the drug is discontinued. Patients should be counseled regarding alternative lines of treatment like anagrelide and pegylated-interferon.
- PMC Free PDF